News

Treatment with Ofev (nintedanib) is safe and can preserve lung function in people with idiopathic pulmonary fibrosis (IPF) who are elderly or have several other health conditions, a new study indicates. The study, “Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who…

Small extracellular vesicles (EVs) released from umbilical cord stem cells seem to carry molecules that can inhibit the TGF-beta signaling pathway and reduce tissue damage in the lungs of mice with pulmonary fibrosis (PF), a study shows. The findings support further research on stem cell-derived EVs as a potential…

Idiopathic pulmonary fibrosis (IPF) is associated with poorer prognosis in patients with lung cancer, a study shows. People with lung cancer showed a higher risk of dying if IPF was present. The findings also suggest that lung cancer treatments, such as chemotherapy, can contribute to poor clinical outcomes by…

Two people with idiopathic pulmonary fibrosis (IPF) and poor lung function underwent chemotherapy for small cell lung cancer (SCLC) while continuing with their antifibrotic treatment, with clinical benefit evident in both. These findings suggest that “chemotherapy can be considered in patients…

SAN903, a candidate therapy for idiopathic pulmonary fibrosis (IPF), led to a significant reduction in markers of inflammation and fibrosis (scarring) in a mouse model of induced pulmonary fibrosis (PF), its developer, Saniona, reported. The treatment’s ability to lessen tissue scarring also outperformed that of Esbriet (pirfenidone),…

More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less than willing to be vaccinated for COVID-19 if a vaccine was approved under emergency use authorization instead of the routine process, the EveryLife Foundation for Rare Disease reports. These findings…

A variant of the MUC5B gene, known as the rs35705950 (T) allele, appears to lead to better survival in people with idiopathic pulmonary fibrosis (IPF) on anti-fibrotic treatment, a study reports. These findings highlight the potential usefulness of MUC5B genetic data in treating and managing these patients. The study,…

United Therapeutics has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) requesting the approval of Tyvaso DPI, an investigational dry powder inhaled formulation of treprostinil, to treat pulmonary hypertension associated with…

Outcomes are as poor in people with progressive fibrosing interstitial lung disease (PF-ILD) other than idiopathic pulmonary fibrosis (IPF) as in those with IPF, according to a Japanese real-world study. Researchers also found that worse lung function at a first assessment and the presence of fibrotic patterns in the…

The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a rare disease pursue personal goals through training and education. For a second year, the #RAREis Scholarship Fund — supported by Horizon Therapeutics – will award 35 one-time scholarships, each…